Devgen pharma plans to reach clinical proof of concept for its inflammatory projects and
then seek partners for further development and commercialization. Regular program
updates are available to interested parties.
There is active interest from several pharma companies in evaluating our small molecule
candidates for various disease indications.
In addition to the inflammation programs, Devgen pharma has 2 attractive programs for
immediate partnering:

Kv4.3/1.5 potassium ion channel inhibitors
Devgen has developed best-in-class, orally bioavailable, potent and atrial-selective small
molecule Kv4.3 / Kv1.5 inhibitors for the acute and chronic treatment of atrial fibrillation
(AF). Inhibition of the potassium channels Kv4.3 and Kv1.5 prolongs the action potential of
the atrium and consequently prolongs the atrial refractory period. This mechanism is known
to enable cardioversion in AF patients and to maintain them in sinus rhythm. Since the
action of these Kv4.3 / Kv1.5 inhibitors is atrial selective, they should have little propensity to
cause life-threatening ventricular arrhythmias as observed for many anti-atrial fibrillation
drugs.
Atrial fibrillation is a frequent and serious heart rhythm abnormality with over eleven million
patients in the seven major markets (Datamonitor, 2006). It leads to fatal complications like
thrombosis, stroke and cardiac failure. Current rhythm control drugs have limited efficacy
and a significant chance to induce fatal ventricular arrhythmias (e.g. torsade de pointes).
This is especially dangerous as the prevalence of AF increases with age and AF patients
often exhibit co-morbidities such as congestive heart failure.

ROCK inhibitors for glaucom
Topical applications of ROCK inhibitors are being developed for the treatment of glaucoma
because of the potential benefit on smooth muscle tone, which may result in improved
outflow of aqueous humor and lowered intraocular pressure. A further benefit may be the anti-inflammatory effects of ROCK inhibition. In fact, ROCK inhibition appears to be the first
new major class of glaucoma therapeutic options since the introduction of beta blockers and
prostaglandins many years ago.